Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia

NCT04674345 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

346

Enrollment

OTHER

Sponsor class

Conditions

Acute Leukemia
Relapse
Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Sorafenib

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]